Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
TVTX Stock Chart & Stats
$34.69
-$0.11(-0.58%)
At close: 4:00 PM EST
$34.69
-$0.11(-0.58%)
Day’s Range― - ―
52-Week Range$12.91 - $36.87
Previous CloseN/A
Volume140.04K
Average Volume (3M)2.00M
Market Cap
$3.10B
Enterprise Value$2.53B
Total Cash (Recent Filing)$254.53M
Total Debt (Recent Filing)$329.75M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Feb 19, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding89,472,330
10 Day Avg. Volume1,591,705
30 Day Avg. Volume1,999,980
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)23.26
Price to Sales (P/S)5.89
P/FCF Ratio-4.06
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue5.80
Enterprise Value/Gross Profit5.94
Enterprise Value/Ebitda-111.96
Forecast
1Y Price Target
$40.09Price Target Upside15.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$493.59M
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesThe DUPLEX study showed that significantly more Filspari patients achieved a desirable proteinuria level compared with those on irbesartan, indicating better treatment outcomes.
Sales PerformanceQ3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.
Therapy AdoptionFILSPARI’s value proposition broadened with new data reinforcing its use as a foundational therapy in IgAN while also validating path forward in FSGS.
Bears Say
Seasonal Sales TrendsPSFs Plateaued Slightly Due To Seasonality, But This Follows Three Quarters Of Strong Growth Leading To Plenty Of Pull-Through.
Travere Therapeutics News
TVTX FAQ
What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $12.91 and its highest was $36.87 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $3.10B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 86 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Oct 30, 2025. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of -$0.304 by $0.584.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is -0.07.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 89,472,330 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of $0.28 in its last earnings report, beating expectations of -$0.304. Following the earnings report the stock price went up 18.583%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Currently, no hedge funds are holding shares in TVTX
Travere Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.09 (15.57% Upside)
$40.09 (15.57% Upside)
Blogger Sentiment
Bullish
TVTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.97%
12-Months-Change
Fundamentals
Return on Equity
-410.78%
Trailing 12-Months
Asset Growth
6.77%
Trailing 12-Months
Company Description
Travere Therapeutics
Travere Therapeutics (TVTX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. The company primarily operates in the pharmaceutical sector, specializing in treatments for conditions such as kidney diseases and metabolic disorders. Travere's core products include its lead drug candidates aimed at addressing significant unmet medical needs in these areas, leveraging advanced scientific research and clinical development to enhance patient outcomes.
TVTX Company Deck
TVTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter characterized by significant growth in FILSPARI sales, potential FDA approval for new indications, and successful manufacturing advancements. However, seasonal trends and a competitive market present challenges.View all TVTX earnings summariesTVTX Stock 12 Month Forecast
Average Price Target
$40.09
▲(15.57% Upside)
Technical Analysis
Galapagos
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
1.51% Insiders
27.41% Mutual Funds
12.44% Other Institutional Investors
42.56% Public Companies and
Individual Investors